TapewireFind a company

person · Reporting owner

FitzPatrick Margaret M

Disclosed activity across 2 companies

Tapewire entity
1086
SEC CIK
0001873879

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
AN2 Therapeutics, Inc.ANTX · Entity 1085DirectorSeptember 01, 2026September 02, 2026
Vistagen Therapeutics, Inc.VTGN · Entity 7955DirectorSeptember 09, 2025September 11, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AN2 Therapeutics, Inc.

Report date September 01, 2026 · Filed September 02, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect10,708 Reported balance After 2026-09-01 transaction · row 1
1 source row

Row 1 · 2026-09-01 · Purchase · Acquired 2,098 · Balance 10,708

Vistagen Therapeutics, Inc.

Report date September 09, 2025 · Filed September 11, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.61 · Expires 2035-09-09Direct17,600 Reported balance After 2025-09-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2025-09-09 · Grant · Acquired 17,600 · Balance 17,600

F1: Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant.

Filing footnotes · ownership attribution and instrument terms

F1: Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 01, 2026 Filed Sep 2, 2026 22:43 UTC AN2 Therapeutics, Inc. ANTX · Entity 1085 PurchaseCommon Stock 2,098 $5.53 $11,601.94
Disclosure

SEC source: 0001193125-26-380595 · ownership.xml · nonDerivative · entry 1

FitzPatrick Margaret M · CIK 0001873879 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,708

Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:09 UTC AN2 Therapeutics, Inc. ANTX · Entity 1085 Disposition to issuerStock Option (right to buy) · Derivative 23,742 Not disclosed Strike: $5.91 Not disclosed
Disclosure

SEC source: 0001193125-26-120221 · ownership.xml · derivative · entry 6

FitzPatrick Margaret M · CIK 0001873879 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 23,742 shares

Expires 2033-06-06

F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

F2 · derivative.exercise_date: The option is fully vested.

Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:09 UTC AN2 Therapeutics, Inc. ANTX · Entity 1085 GrantStock Option (right to buy) · Derivative 23,742 Not disclosed Strike: $3.91 Not disclosed
Disclosure

SEC source: 0001193125-26-120221 · ownership.xml · derivative · entry 5

FitzPatrick Margaret M · CIK 0001873879 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,742

Underlying: Common Stock · 23,742 shares

Expires 2033-06-06

F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.

F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

F2 · derivative.exercise_date: The option is fully vested.

Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:09 UTC AN2 Therapeutics, Inc. ANTX · Entity 1085 Disposition to issuerStock Option (right to buy) · Derivative 10,362 Not disclosed Strike: $17.28 Not disclosed
Disclosure

SEC source: 0001193125-26-120221 · ownership.xml · derivative · entry 4

FitzPatrick Margaret M · CIK 0001873879 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,362 shares

Expires 2032-05-11

F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

F2 · derivative.exercise_date: The option is fully vested.

Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:09 UTC AN2 Therapeutics, Inc. ANTX · Entity 1085 GrantStock Option (right to buy) · Derivative 10,362 Not disclosed Strike: $3.91 Not disclosed
Disclosure

SEC source: 0001193125-26-120221 · ownership.xml · derivative · entry 3

FitzPatrick Margaret M · CIK 0001873879 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,362

Underlying: Common Stock · 10,362 shares

Expires 2032-05-11

F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.

F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

F2 · derivative.exercise_date: The option is fully vested.

Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:09 UTC AN2 Therapeutics, Inc. ANTX · Entity 1085 Disposition to issuerStock Option (right to buy) · Derivative 11,463 Not disclosed Strike: $18.24 Not disclosed
Disclosure

SEC source: 0001193125-26-120221 · ownership.xml · derivative · entry 2

FitzPatrick Margaret M · CIK 0001873879 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,463 shares

Expires 2032-05-04

F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

F2 · derivative.exercise_date: The option is fully vested.

Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:09 UTC AN2 Therapeutics, Inc. ANTX · Entity 1085 GrantStock Option (right to buy) · Derivative 11,463 Not disclosed Strike: $3.91 Not disclosed
Disclosure

SEC source: 0001193125-26-120221 · ownership.xml · derivative · entry 1

FitzPatrick Margaret M · CIK 0001873879 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,463

Underlying: Common Stock · 11,463 shares

Expires 2032-05-04

F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.

F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

F2 · derivative.exercise_date: The option is fully vested.

Read SEC document
February 20, 2026 Filed Feb 23, 2026 21:17 UTC AN2 Therapeutics, Inc. ANTX · Entity 1085 GrantStock Option (Right to Buy) · Derivative 20,400 $0.00 Strike: $1.04 $0.00
Disclosure

SEC source: 0001193125-26-064028 · ownership.xml · derivative · entry 1

FitzPatrick Margaret M · CIK 0001873879 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,400

Underlying: Common Stock · 20,400 shares

Expires 2036-02-19

F1 · derivative.exercise_date: The option shares shall vest on February 20, 2027, subject to the Reporting Person providing continuous service through such date.

Read SEC document
September 09, 2025 Filed Sep 11, 2025 22:15 UTC Vistagen Therapeutics, Inc. VTGN · Entity 7955 GrantNon-Qualified Stock Option (right to buy) · Derivative 17,600 $0.00 Strike: $3.61 $0.00
Disclosure

SEC source: 0001411685-25-000076 · edgardoc.xml · derivative · entry 1

FitzPatrick Margaret M · CIK 0001873879 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,600

Underlying: Common Stock · 17,600 shares

Expires 2035-09-09

F1 · derivative.exercise_date: Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant.

Read SEC document
May 28, 2025 Filed May 29, 2025 20:17 UTC AN2 Therapeutics, Inc. ANTX · Entity 1085 PurchaseCommon Stock 8,610 $1.18 $10,133.11
Disclosure

SEC source: 0000950170-25-078982 · ownership.xml · nonDerivative · entry 1

FitzPatrick Margaret M · CIK 0001873879 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,610

F1 · price: This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.17 to $1.18 per share. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price.

Read SEC document
May 22, 2025 Filed May 23, 2025 20:59 UTC AN2 Therapeutics, Inc. ANTX · Entity 1085 GrantStock Option (Right to Buy) · Derivative 19,111 $0.00 Strike: $1.19 $0.00
Disclosure

SEC source: 0000950170-25-077062 · ownership.xml · derivative · entry 1

FitzPatrick Margaret M · CIK 0001873879 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,111

Underlying: Common Stock · 19,111 shares

Expires 2035-05-21

F1 · derivative.exercise_date: The option shares shall vest on March 31, 2026, subject to the Reporting Person providing continuous service through such date.

Read SEC document
September 06, 2024 Filed Sep 10, 2024 21:00 UTC Vistagen Therapeutics, Inc. VTGN · Entity 7955 GrantStock Option (Right to Buy) · Derivative 14,100 $0.00 Strike: $3.25 $0.00
Disclosure

SEC source: 0001415889-24-023145 · form4-09102024_050903.xml · derivative · entry 1

FitzPatrick Margaret M · CIK 0001873879 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,100

Underlying: Common Stock · 14,100 shares

Expires 2034-09-06

F1 · derivative.exercise_date: Represents stock options ("Options") granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. Twenty-five percent (25%) of the Options vest on the date of issuance ("Grant Date"), with the remainder vesting in twelve (12) equal monthly installments thereafter, until the Options become fully vested on the one (1) year anniversary of the Grant Date.

Read SEC document
June 19, 2024 Filed Jun 21, 2024 22:18 UTC AN2 Therapeutics, Inc. ANTX · Entity 1085 GrantStock Option (Right to Buy) · Derivative 64,503 $0.00 Strike: $2.00 $0.00
Disclosure

SEC source: 0000950170-24-076406 · ownership.xml · derivative · entry 1

FitzPatrick Margaret M · CIK 0001873879 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,503

Underlying: Common Stock · 64,503 shares

Expires 2034-06-18

F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the one-year anniversary of June 19, 2024 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date.

Read SEC document
March 04, 2024 Filed Mar 6, 2024 23:00 UTC Vistagen Therapeutics, Inc. VTGN · Entity 7955 GrantStock Option (Right to Buy) · Derivative 12,500 $0.00 Strike: $4.85 $0.00
Disclosure

SEC source: 0001415889-24-007097 · form4-03062024_060311.xml · derivative · entry 1

FitzPatrick Margaret M · CIK 0001873879 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2034-03-04

F1 · derivative.exercise_date: Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant.

Read SEC document
June 07, 2023 Filed Jun 10, 2023 00:54 UTC AN2 Therapeutics, Inc. ANTX · Entity 1085 GrantStock Option (right to buy) · Derivative 23,742 $0.00 Strike: $5.91 $0.00
Disclosure

SEC source: 0000899243-23-015320 · doc4.xml · derivative · entry 1

FitzPatrick Margaret M · CIK 0001873879 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,742

Underlying: Common Stock · 23,742 shares

Expires 2033-06-06

F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the one-year anniversary of June 7, 2023 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date.

Read SEC document
May 12, 2022 Filed May 17, 2022 01:20 UTC AN2 Therapeutics, Inc. ANTX · Entity 1085 GrantStock Option (right to buy) · Derivative 10,362 $0.00 Strike: $17.28 $0.00
Disclosure

SEC source: 0000899243-22-018286 · doc4.xml · derivative · entry 1

FitzPatrick Margaret M · CIK 0001873879 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,362

Underlying: Common Stock · 10,362 shares

Expires 2032-05-11

F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/12 of the shares shall vest on each monthly anniversary as measured from May 5, 2022.

Read SEC document
May 05, 2022 Filed May 10, 2022 01:39 UTC AN2 Therapeutics, Inc. ANTX · Entity 1085 GrantStock Option (right to buy) · Derivative 11,463 $0.00 Strike: $18.24 $0.00
Disclosure

SEC source: 0000899243-22-017371 · doc4.xml · derivative · entry 1

FitzPatrick Margaret M · CIK 0001873879 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,463

Underlying: Common Stock · 11,463 shares

Expires 2032-05-04

F1 · derivative.exercise_date: The shares subject to the Option shall vest on a monthly basis over a three-year period as measured from May 5, 2022.

Read SEC document
March 01, 2022 Filed Mar 3, 2022 21:13 UTC Vistagen Therapeutics, Inc. VTGN · Entity 7955 GrantStock Option (Right to Buy) · Derivative 100,000 $0.00 Strike: $1.37 $0.00
Disclosure

SEC source: 0001415889-22-002291 · form4-03032022_010341.xml · derivative · entry 1

FitzPatrick Margaret M · CIK 0001873879 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2032-03-01

F1 · derivative.exercise_date: Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, which vest in twelve equal monthly installments, beginning on the date of the grant.

Read SEC document
July 21, 2021 Filed Jul 22, 2021 20:11 UTC Vistagen Therapeutics, Inc. VTGN · Entity 7955 GrantStock Option (Right to Buy) · Derivative 75,000 $0.00 Strike: $2.93 $0.00
Disclosure

SEC source: 0001415889-21-003674 · form4-07222021_010706.xml · derivative · entry 1

FitzPatrick Margaret M · CIK 0001873879 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2031-07-21

F1 · derivative.exercise_date: The stock options vest in twelve equal monthly installments, beginning on the date of the grant. The stock options were granted in connection with the Reporting Person's appointment to the Issuer's Board of Directors and pursuant to the Issuer's 2019 Omnibus Equity Incentive Plan.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.